FDA rescinds Emergency Use Authorization of Eli Lilly’s ‘bamlanivimab’ monoclonal antibody treatment
The FDA has rescinded its Emergency Use Authorization of Eli Lilly’s ‘bamlanivimab,’ the monoclonal antibody treatment for COVID-19, to be used on its own